We collected interim bone marrow aspirates (BMAs; 27 days postengraftment and 14 days of treatment) and found a marked reduction in tumor burden indicated by reduced human CD45 (hCD45) percentage in HOSU-53 arms (Figure 6B). This evidence concerns the gene PTPRC and neoplasm.